Company profile

Ticker
BAX
Exchange
Website
CEO
José E. Almeida
Employees
Incorporated in
Location
Fiscal year end
SEC CIK
IRS number
360781620

BAX stock data

(
)

Calendar

30 Apr 20
8 Jul 20
31 Dec 20

News

Company financial data Financial data

Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Revenue 2.8B 3.04B 2.85B 2.83B
Net income 333M -19M 375M 313M
Diluted EPS 0.64 -0.05 0.71 0.6
Net profit margin 11.88% -0.63% 13.15% 11.04%
Operating income 409M 536M 503M 350M
Net change in cash 775M 326M 75M 1.03B
Cash on hand 4.11B 3.34B 3.01B 2.93B
Cost of revenue 1.64B 1.74B 1.62B 1.68B
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 11.36B 11.1B 10.56B 10.16B
Net income 1.01B 1.55B 602M 4.97B
Diluted EPS 1.93 2.83 1.08 9.01
Net profit margin 8.90% 13.93% 5.70% 48.85%
Operating income 1.77B 1.58B 1.29B 745M
Net change in cash 1.5B -1.56B 593M 588M
Cash on hand 3.34B 1.84B 3.39B 2.8B
Cost of revenue 6.6B 6.34B 6.11B 6.05B

Financial data from company earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
19 Jun 20 Accogli Giuseppe Common Stock, $1 par value Sell Dispose S Yes 85 72,341 6.15M 66,520
19 Jun 20 Accogli Giuseppe Common Stock, $1 par value Option exercise Aquire M Yes 46.18 8,334 384.86K 76,473
19 Jun 20 Accogli Giuseppe Stock Option [Right to Buy) Common Stock, $1 par value Option exercise Dispose M Yes 50.77 62,388 3.17M 31,195
19 Jun 20 Accogli Giuseppe Stock Option Common Stock, $1 par value Option exercise Dispose M Yes 46.18 8,334 384.86K 0
19 Jun 20 Accogli Giuseppe Common Stock, $1 par value Option exercise Aquire M Yes 50.77 62,388 3.17M 138,861
15 Jun 20 Forsyth John D Common Stock, $1 par value Sell Dispose S No 82.95 1,500 124.43K 33,898
15 Jun 20 Forsyth John D Common Stock, $1 par value Option exercise Aquire M Yes 31.26 1,500 46.89K 35,398
15 Jun 20 Forsyth John D Stock Option Common Stock, $1 par value Option exercise Dispose M Yes 31.26 1,500 46.89K 310
8 Jun 20 Franzi Cristiano Common Stock, $1 par value Sell Dispose S No 87.96 22,700 2M 39,088
8 Jun 20 Franzi Cristiano Common Stock, $1 par value Sell Dispose S No 87.33 23,900 2.09M 61,788
83.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1076 1126 -4.4%
Opened positions 76 151 -49.7%
Closed positions 126 94 +34.0%
Increased positions 291 336 -13.4%
Reduced positions 490 412 +18.9%
13F shares
Current Prev Q Change
Total value 34.51B 35.52B -2.8%
Total shares 424.9M 424.7M +0.0%
Total puts 876.1K 1.43M -38.9%
Total calls 1.13M 2.52M -55.3%
Total put/call ratio 0.8 0.6 +36.9%
Largest owners
Shares Value Change
BLK BlackRock 41.29M $3.35B +1.2%
Vanguard 40.33M $3.27B +2.6%
Wellington Management 29.92M $2.43B -4.2%
STT State Street 23.57M $1.92B -1.3%
MS Morgan Stanley 19.41M $1.58B +7.6%
FMR 13.89M $1.13B +2.9%
Third Point 11.58M $940.18M -33.8%
Generation Investment Management 10.16M $824.94M +49.0%
AMP Ameriprise Financial 9.24M $749.79M -11.3%
Veritas Asset Management 8.95M $726.89M +23.3%
Largest transactions
Shares Bought/sold Change
JPM JPMorgan Chase & Co. 7.94M +7.37M +1291.7%
Norges Bank 0 -7.11M EXIT
Third Point 11.58M -5.92M -33.8%
Generation Investment Management 10.16M +3.34M +49.0%
Brown Brothers Harriman & Co 3.18M +3.15M +10430.4%
Putnam Investments 3.48M +2.74M +374.8%
Capital International Investors 7.27M +2.7M +59.2%
Lazard Asset Management 5.07M -1.7M -25.2%
Veritas Asset Management 8.95M +1.69M +23.3%
BNS The Bank of Nova Scotia 1.51M +1.4M +1292.1%

Financial report summary

?
Management Discussion
  • Net income attributable to Baxter stockholders for the three months ended March 31, 2020 totaled $332 million, or $0.64 per diluted share, compared to $342 million, or $0.66 per diluted share, for the three months ended March 31, 2019. Net income for the three months ended March 31, 2020 included special items which decreased net income by $93 million, or $0.18 per diluted share, as further discussed below. Net income for the three months ended March 31, 2019 included special items which decreased net income by $52 million, or $0.09 per diluted share, as further discussed below.
  • Intangible asset amortization expense is identified as a special item to facilitate an evaluation of current and past operating performance and is consistent with how management and our Board of Directors assess performance. Additional special items are identified above because they are highly variable, difficult to predict and of a size that may substantially impact our reported results of operations for the period. Management believes that providing the separate impact of those items may provide a more complete understanding and facilitate a fuller analysis of our results of operations, particularly in evaluating performance from one period to another.
  • 1In 2020 and 2019, our results were impacted by costs associated with our execution of programs to optimize our organization and cost structure on a global basis. These actions included streamlining our international operations, rationalizing our manufacturing facilities, reducing our general and administrative infrastructure, re-aligning certain R&D activities and cancelling certain R&D programs. Our results in 2020 and 2019 included business optimization charges of $32 million and $38 million, respectively. Additionally, we recognized a gain of $17 million in 2020 for property we sold in conjunction with our business optimization
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: annum, compel, default, divided, doubtful, drove, event, finalize, forma, guaranteed, identical, interbank, Kingdom, LIBOR, lifetime, London, met, offer, offered, Overnight, pandemic, postponed, preliminary, pro, provision, relationship, revert, Scop, SOFR, successor, Transderm, vintage, widely
Removed: apply, approved, ASR, assessing, Australia, bank, borrow, borrowing, BREVIBLOC, Celerity, charge, China, classify, collateralized, Committee, comparability, cooperating, determine, direct, enactment, expedient, FASB, flat, funded, guidance, ii, iii, index, LLC, maintenance, nontaxable, office, paper, practical, provisional, ranging, reclassification, seller, shorter, simplify, supplemental, Targeted, taxing, volume

Patents

GRANT
Utility
Packaging system and methods of alerting a practitioner
7 Jul 20
A packaging system includes a container having a closed end an open end, a longitudinal axis running through the closed end and the open end, and an outer surface.
GRANT
Utility
Drain and fill logic for automated peritoneal dialysis
7 Jul 20
A system for performing a peritoneal dialysis therapy includes at least one dialysis fluid pump, and a logic implementer operable with the at least one dialysis fluid pump to perform a plurality of peritoneal dialysis cycles, the cycles including a fill phase, a dwell phase and a drain phase, the logic implementer configured to: (i) store a first peritoneal dialysis treatment having a total prescribed fresh dialysis fluid fill volume delivered over a number of cycles; and (ii) convert the first peritoneal dialysis treatment into a second peritoneal dialysis treatment having a different number of cycles and using the same total prescribed fresh dialysis fluid fill volume.
GRANT
Utility
Renal therapy machine and method including a priming sequence
30 Jun 20
A method for priming a renal therapy machine is disclosed.
APP
Utility
Dialysis System Including Dextrose Mixing
11 Jun 20
An automated peritoneal dialysis system and machine configured to perform dextrose mixing are disclosed.
APP
Utility
Apparatus for Extracorporeal Treatment of Blood and Method of Priming an Extracorporeal Blood Circuit
11 Jun 20
An extracorporeal blood treatment apparatus comprises: a blood treatment device (2); an extracorporeal blood circuit comprising a blood withdrawal line (6) and a blood return line (7) coupled to the extracorporeal blood treatment device (2), wherein the blood return line (7) presents a heating zone (14) coupled or configured to be coupled to a blood warmer (15); a blood pump (6) configured to be coupled to a pump section of the blood withdrawal line (6); at least a post-infusion line (13, 13′) connected to the blood return line (7) upstream of the heating zone (14); an air trapping device (9) placed on the blood return line (7) upstream of the heating zone (14).